Brain Tumor Diagnosis and Therapeutics Market By Diagnosis Type (Imaging Techniques (MRI (Magnetic Resonance Imaging), CT (Computed Tomography), PET (Positron Emission Tomography), Other Imaging Techniques), Biopsy, Molecular Diagnostics); By Therapeutics Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy); By Tumor Type (Glioblastoma, Meningioma, Pituitary Tumors, Astrocytomas, Other Tumors); By End User (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers (ASCs), Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

The global brain tumor diagnosis and therapeutics market was worth USD 5.5 billion in 2023 and is expected to reach USD 9.7 billion by 2030 with CAGR of 8.3%. This growth is due to the rising cases of brain tumors, the general increase in health care costs, and improvement to the techniques used in the treatment of brain tumors.

 

Brain tumors are a complicated medical problem that necessitates the use of sophisticated diagnostics and treatment strategies. It can be either cancerous or noncancerous and can be predicted with simple symptoms such as headaches, nausea, or even advanced neurological deficits. The global brain tumor diagnosis and therapeutics market is growing rapidly because of enhanced diagnostic imaging techniques, personalized medicine, and new treatment opportunities, including targeted therapy and immunotherapy.

 

Market Dynamics (Forces Shaping the Future: Key Drivers in the Brain Tumor Diagnosis Market)

Rising number of Brain Tumor cases

The WHO estimates that 308,102 new cases of brain and central nervous system tumors were diagnosed in 2020, and more than 251,000 deaths occur annually due to these tumors. The increasing incidence has thus called for early diagnosis and efficient intervention therapy.

 

Diagnostic Imaging and Technologies

Modern diagnosis methods include MRI, CT scan, and PET imaging, which have been developed to detect brain tumors. For instance, the application of 7T MRI scanners has enhanced tumor images and led to improved early diagnoses.

 

Increasing Usage of Targeted Medications and Immunotherapy

Bevacizumab (Avastin) and Temozolomide have been approved as treatments for glioblastoma, the most deadly type of brain tumor. Perhaps there is no field in modern oncology that has such tremendous potential as immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, which are also effective in clinical trials.

 

Higher Current and Anticipated Healthcare Costs and Health Illiteracy

Increased healthcare expenditures in various parts of the developing world and newly launched awareness campaigns are promoting early diagnosis. For instance, in the year 2023, the National Brain Tumor Society in the United States launched the Global Awareness and Research Funding Campaign.

 

The Convergence of Technology and Treatment: Opportunities in Advanced Neuro-Oncology

New Directions in Emerging Markets: Asia-Pacific

Newer markets such as India and China are experiencing growth in healthcare investment and infrastructure, hence experiencing a boost in the diagnostic and treatment of brain tumors. For instance, it has been projected that the healthcare market of India will reach about $372 billion by the year 2030 through policies such as Ayushman Bharat.

 

Application of Artificial Intelligence (AI) in Diagnostic

Machine learning algorithms, including those by the California-based Zebra Medical Vision, are already being employed to analyze brain imaging information with improved speed and precision.

 

The field of Personalized Medicine and Biomarker Research

Genomic and proteomic improvements have produced biomarkers of the disease, including EGFR and MGMT, which have led to the creation of more targeted treatments. Many of these innovations are expected to revolutionize the market by enhancing the efficacy of treatment while minimizing the side effects.

 

High Costs, High Barriers: Addressing Financial Challenges in Brain Tumor Treatment

Expensive diagnostic methods and cost of treatment

The expenses related to diagnostic imaging and therapeutic procedures are still unaffordable to many patients. For instance, an MRI scan may cost between $1000 and $5000 in developed MS health facilities, while proton therapy costs above $100,000 for each patient.

 

Reduced Opportunity to Receive Complex Medical Products in Emerging Markets

In parts of Sub-Saharan Africa and some parts of South East Asia, the lack of health facilities and qualified personnel poses a major challenge for brain tumor diagnosis and treatment.

 

From Imaging to Intervention: Exploring the Market's Key Segments

By Diagnosis Type

• Imaging Techniques

  • MRI (Magnetic Resonance Imaging)

  • CT (Computed Tomography)

  • PET (Positron Emission Tomography)

  • Other Imaging Techniques

• Biopsy

• Molecular Diagnostics

 

By Therapeutics Type

• Surgery

• Radiation Therapy

• Chemotherapy

• Targeted Therapy

• Immunotherapy

 

By Tumor Type

• Glioblastoma

• Meningioma

• Pituitary Tumors

• Astrocytomas

• Other Tumors

 

By End User

• Hospitals

• Diagnostic Centers

• Ambulatory Surgical Centers (ASCs)

• Research Institutes

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Segment Analysis of Brain Tumor Diagnosis and Therapeutics Market

By Diagnosis Type:

Leading Segment: Imaging Techniques (MRI)

MRI (Magnetic Resonance Imaging) is the leading segment in the brain tumor diagnosis market, holding the largest market share due to its non-invasive nature and high-resolution imaging capabilities. MRI plays a critical role in detecting, diagnosing & monitoring brain tumors, offering detailed images of soft tissues in the brain. It is widely used in both clinical and research settings for its accuracy in distinguishing between benign and malignant tumors. The global MRI market is valued at over 60% of the overall brain tumor diagnosis market. In 2024, it is estimated to contribute significantly, particularly in developed markets such as North America & Europe, where healthcare infrastructure supports advanced diagnostic technologies.

Fastest-Growing Segment: Molecular Diagnostics

Molecular diagnostics is the fastest-growing segment, expanding at a CAGR of 8-10%. This segment is driven by advancements in genetic profiling & biomarkers, allowing for more personalized and targeted diagnostic approaches. The ability to detect specific genetic mutations associated with brain tumors enables earlier diagnosis & better prognosis prediction. Molecular diagnostics is increasingly used alongside imaging techniques to offer a comprehensive view of tumor characteristics, thus boosting its demand in both research & clinical settings.

 

By Therapeutics Type:

Leading Segment: Surgery

Surgery remains the leading therapeutic option in the treatment of brain tumors, making up the largest share of the therapeutics market. Surgical intervention is often the first line of treatment for accessible brain tumors, with the aim of removing or reducing tumor size. The segment is driven by advances in neurosurgical techniques, such as minimally invasive surgery and robot-assisted surgery, which improve outcomes and reduce recovery time. Surgery accounts for a major share due to its critical role in both diagnosis and treatment, particularly for tumors located in operable areas of the brain.

Fastest-Growing Segment: Immunotherapy

Immunotherapy is the fastest-growing segment within brain tumor therapeutics, with a CAGR of 15-17%. The rise in immunotherapy treatments, such as checkpoint inhibitors & vaccine-based therapies, is transforming the treatment landscape for brain tumors, particularly glioblastoma, which is often resistant to traditional therapies. Immunotherapy aims to enhance the body’s immune response to fight brain tumors more effectively, offering hope for patients with aggressive forms of brain cancer. Increased research investment, along with FDA approvals for certain immunotherapy drugs, is expected to drive significant growth in this segment.

 

By Tumor Type:

Leading Segment: Glioblastoma

Glioblastoma is the leading tumor type in the brain tumor diagnosis and therapeutics market, occupying the largest market share. It is one of the most aggressive & common malignant brain tumors in adults. Glioblastoma accounts for approximately 50-60% of all primary brain tumors. The high mortality rate associated with glioblastoma, along with its resistance to conventional treatments, makes it the focal point for both diagnostic & therapeutic developments. The FDA has approved a new targeted drug specifically for low-grade gliomas. The drug, vorasidenib, was shown in clinical trials to delay the progression of low-grade gliomas with mutations in the IDH1 or IDH2 genes. Advances in targeted therapy, immunotherapy, and personalized medicine are crucial drivers for market growth in this segment.

Fastest-Growing Segment: Meningioma

Meningioma is the fastest-growing tumor type segment in the brain tumor market, growing at a CAGR of 6-8%. Meningiomas are more common than glioblastomas and are often benign, though they can cause significant symptoms due to their location. This growth is attributed to the increasing detection of meningiomas in early-stage patients, coupled with advances in non-invasive treatment methods, such as stereotactic radiosurgery. Rising awareness & advances in imaging technologies contribute to the growing diagnosis and treatment of meningiomas, driving the expansion of this segment.

 

By End User:

Leading Segment: Hospitals

Hospitals represent the largest end-user segment for both brain tumor diagnosis and therapeutics, holding the majority of the market share. Hospitals are the primary treatment centers for patients undergoing surgery, radiation therapy, and chemotherapy for brain tumors. In addition, most diagnostic imaging procedures, such as MRIs and CT scans, are conducted in hospital settings. The extensive healthcare infrastructure & access to advanced technologies in hospitals continue to drive their dominance in the market.

Fastest-Growing Segment: Ambulatory Surgical Centers

Ambulatory Surgical Centers (ASCs) are the fastest-growing segment, with a CAGR of 10-12%. ASCs offer less expensive & more convenient treatment options for patients requiring minor neurosurgical interventions or follow-up treatments. The trend toward outpatient procedures & the rise in minimally invasive surgeries have contributed to the growth of this segment. ASCs are becoming an increasingly attractive option due to their ability to provide quality care at a lower cost, thereby driving demand in the brain tumor treatment market.

 

By Region:

Leading Region: North America

North America holds the largest market share in the brain tumor diagnosis and therapeutics market, driven by the strong healthcare infrastructure, high investment in research & availability of advanced treatment options. The United States, in particular, is a leader in brain tumor research, with leading institutions and hospitals offering cutting-edge diagnostic and therapeutic services. The number of cancer survivors in the United States is expected to rise to more than 26 million by 2040. These trends reflect advances in cancer detection, diagnosis, and patient care that have resulted in people living longer, healthier lives than ever before. The increasing prevalence of brain tumors, coupled with government & private funding for research, further solidifies North America as the dominant region in the market.

Fastest-Growing Region: Asia-Pacific

The Asia-Pacific (APAC) region is the fastest-growing market for brain tumor diagnosis and therapeutics, with a CAGR of 7-9%. The increasing incidence of brain tumors in countries like China and India, along with improving healthcare infrastructure, is driving the market in this region. APAC is experiencing rapid advancements in diagnostic technologies & therapeutic techniques, and there is a growing demand for specialized brain tumor treatments due to rising awareness and a shift toward advanced healthcare services. Government initiatives aimed at increasing access to healthcare are also contributing to the growth of this segment in the region.

 

Strategic Leaders: Key Players Advancing Brain Tumor Care Worldwide

• F. Hoffmann-La Roche Ltd.

• Novartis AG

• Merck & Co., Inc.

• Pfizer Inc.

• AstraZeneca PLC

• Bristol-Myers Squibb Company

• GE Healthcare

• Siemens Healthineers AG

• Elekta AB

 

Brain Tumor Diagnosis and Therapeutics Market Report Coverage

Report Attribute	Details
Forecast Period	2023 – 2030
Market Size Value in 2023	USD 5.5 billion
Revenue Forecast in 2030	USD 9.7 billion
Overall Growth Rate	CAGR of 8.3% (2023 – 2030)
Base Year for Estimation	2023
Historical Data	2018 – 2022
Unit	USD Billion, CAGR
Segmentation	By Diagnosis Type, By Therapeutic Area, By Region
By Diagnosis Type	Imaging, Biopsy, MRI, CT scan
By Therapeutic Area	Surgery, Radiation Therapy, Chemotherapy, Immunotherapy
By Region	North America, Europe, Asia-Pacific, Latin America
Country Scope	US, Canada, Germany, UK, France, China, Japan, India, etc.
Key Market Drivers	Increasing prevalence of brain tumors, advancements in diagnostic technologies, and rising healthcare investments.
Major Players	Merck, Roche, Eli Lilly, Pfizer, Novartis
Pricing and Purchase Options	Custom pricing options available for detailed market insights.

 

AI, Genomics, and Innovation: The Future of Brain Tumor Diagnostics

The brain tumor diagnosis and therapeutics market has tremendous potential for growth in the future due to technological development, personalized medicine, and developing international healthcare investments. Such trends include the infusion of Artificial intelligence and machine learning in diagnostics, the ascendance of minimally invasive surgery, and new forms of treatments, including gene editing and oncolytic virotherapy.

New entrants aiming to develop and provide inexpensive and accessible solutions are likely to record massive market adoption, most notably in the developing world. In addition, as awareness and early intervention campaigns for cancer increase, the need for effective diagnostic and treatment technologies will also increase.

Therefore, the brain tumor diagnosis and therapeutics market is set to undergo a drastic change in the next decade, providing hope for patients and opening up opportunities for its development. ICT companies investing in research into developed technologies and related partnerships will be well placed to capitalize on this rapidly growing market.